Download PDF
Int J Angiol 2021; 30(01): 067-075
DOI: 10.1055/s-0041-1723944
Review Article

Management of ST Elevation Myocardial Infarction (STEMI) in Different Settings

Rod Partow-Navid
1   Department of Cardiology, St Bernardine Medical Center, San Bernardino, California
2   UC Riverside School of Medicine, Riverside, California
,
Narut Prasitlumkum
1   Department of Cardiology, St Bernardine Medical Center, San Bernardino, California
2   UC Riverside School of Medicine, Riverside, California
,
Ashish Mukherjee
1   Department of Cardiology, St Bernardine Medical Center, San Bernardino, California
2   UC Riverside School of Medicine, Riverside, California
,
Padmini Varadarajan
1   Department of Cardiology, St Bernardine Medical Center, San Bernardino, California
2   UC Riverside School of Medicine, Riverside, California
,
Ramdas G. Pai 
1   Department of Cardiology, St Bernardine Medical Center, San Bernardino, California
2   UC Riverside School of Medicine, Riverside, California
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

ST-segment elevation myocardial infarction (STEMI) is a life-threatening condition that requires emergent, complex, well-coordinated treatment. Although the primary goal of treatment is simple to describe—reperfusion as quickly as possible—the management process is complicated and is affected by multiple factors including location, patient, and practitioner characteristics. Hence, this narrative review will discuss the recommended management and treatment strategies of STEMI in the circumstances.

Keywords

acute coronary syndrome - PCI - thrombolysis - STEMI - management - review article - different settings


Publication History

Article published online:
24 March 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Thygesen K, Alpert JS, Jaffe AS. et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018; 138 (20) e618-e651
    CrossrefPubMedGoogle Scholar
  • 2 Benjamin EJ, Muntner P, Alonso A. et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019; 139 (10) e56-e528
    CrossrefPubMedGoogle Scholar
  • 3 Torio CMMB. National inpatient hospital costs: the most expensive conditions by payer, 2013, Statistical Brief #204. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006
    Google Scholar
  • 4 Braunwald E. The treatment of acute myocardial infarction: the past, the present, and the future. Eur Heart J Acute Cardiovasc Care 2012; 1 (01) 9-12
    CrossrefPubMedGoogle Scholar
  • 5 Steg PG, Bonnefoy E, Chabaud S. et al; Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108 (23) 2851-2856
    CrossrefPubMedGoogle Scholar
  • 6 Danchin N, Coste P, Ferrières J. et al; FAST-MI Investigators. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008; 118 (03) 268-276
    CrossrefPubMedGoogle Scholar
  • 7 Sinnaeve PR, Armstrong PW, Gershlick AH. et al; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation 2014; 130 (14) 1139-1145
    CrossrefPubMedGoogle Scholar
  • 8 Roule V, Ardouin P, Blanchart K. et al. Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Crit Care 2016; 20 (01) 359
    CrossrefPubMedGoogle Scholar
  • 9 Armstrong PW, Gershlick AH, Goldstein P. et al; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368 (15) 1379-1387
    CrossrefPubMedGoogle Scholar
  • 10 O'Gara PT, Kushner FG, Ascheim DD. et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (04) e362-e425
    PubMedGoogle Scholar
  • 11 Ibanez B, James S, Agewall S. et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 12 Hsia RY, Shen YC. Percutaneous coronary intervention in the United States: risk factors for untimely access. Health Serv Res 2016; 51 (02) 592-609
    CrossrefPubMedGoogle Scholar
  • 13 Scholz KH, Maier SKG, Maier LS. et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J 2018; 39 (13) 1065-1074
    CrossrefPubMedGoogle Scholar
  • 14 Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343 (8893): 311-322
    CrossrefPubMedGoogle Scholar
  • 15 Pinto DS, Frederick PD, Chakrabarti AK. et al; National Registry of Myocardial Infarction Investigators. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation 2011; 124 (23) 2512-2521
    CrossrefPubMedGoogle Scholar
  • 16 Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348 (9030): 771-775
    CrossrefPubMedGoogle Scholar
  • 17 De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109 (10) 1223-1225
    CrossrefPubMedGoogle Scholar
  • 18 Brodie BR, Webb J, Cox DA. et al; EMERALD Investigators. Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). Am J Cardiol 2007; 99 (12) 1680-1686
    CrossrefPubMedGoogle Scholar
  • 19 Newby LK, Rutsch WR, Califf RM. et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996; 27 (07) 1646-1655
    CrossrefPubMedGoogle Scholar
  • 20 Berger AK, Radford MJ, Krumholz HM. Factors associated with delay in reperfusion therapy in elderly patients with acute myocardial infarction: analysis of the cooperative cardiovascular project. Am Heart J 2000; 139 (06) 985-992
    CrossrefPubMedGoogle Scholar
  • 21 McNamara RL, Herrin J, Wang Y. et al. Impact of delay in door-to-needle time on mortality in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007; 100 (08) 1227-1232
    CrossrefPubMedGoogle Scholar
  • 22 de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38 (05) 1283-1294
    CrossrefPubMedGoogle Scholar
  • 23 Ross AM, Molhoek P, Lundergan C. et al; HART II Investigators. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104 (06) 648-652
    CrossrefPubMedGoogle Scholar
  • 24 Sutton AG, Campbell PG, Graham R. et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004; 44 (02) 287-296
    CrossrefPubMedGoogle Scholar
  • 25 Fernandez-Avilés F, Alonso JJ, Castro-Beiras A. et al; GRACIA (Grupo de Análisis de la Cardiopatía Isquémica Aguda) Group. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364 (9439): 1045-1053
    CrossrefPubMedGoogle Scholar
  • 26 Cantor WJ, Fitchett D, Borgundvaag B. et al; TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360 (26) 2705-2718
    CrossrefPubMedGoogle Scholar
  • 27 Killip III T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20 (04) 457-464
    CrossrefPubMedGoogle Scholar
  • 28 Goldberg RJ, Gore JM, Alpert JS. et al. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991; 325 (16) 1117-1122
    CrossrefPubMedGoogle Scholar
  • 29 Hochman JS, Boland J, Sleeper LA. et al; SHOCK Registry Investigators. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. Circulation 1995; 91 (03) 873-881
    CrossrefPubMedGoogle Scholar
  • 30 van Diepen S, Katz JN, Albert NM. et al; American Heart Association Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary Management of Cardiogenic Shock: A Scientific Statement from the American Heart Association. Circulation 2017; 136 (16) e232-e268
    CrossrefPubMedGoogle Scholar
  • 31 Hochman JS, Sleeper LA, Webb JG. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341 (09) 625-634
    CrossrefPubMedGoogle Scholar
  • 32 Holmes Jr DR, Bates ER, Kleiman NS. et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26 (03) 668-674
    CrossrefPubMedGoogle Scholar
  • 33 Gu YL, Svilaas T, van der Horst IC, Zijlstra F. Conditions mimicking acute ST-segment elevation myocardial infarction in patients referred for primary percutaneous coronary intervention. Neth Heart J 2008; 16 (10) 325-331
    CrossrefPubMedGoogle Scholar
  • 34 Widimsky P, Stellova B, Groch L. et al; PRAGUE Study Group Investigators. Prevalence of normal coronary angiography in the acute phase of suspected ST-elevation myocardial infarction: experience from the PRAGUE studies. Can J Cardiol 2006; 22 (13) 1147-1152
    CrossrefPubMedGoogle Scholar
  • 35 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361 (9351): 13-20
    CrossrefPubMedGoogle Scholar
  • 36 EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342 (8874): 767-772
    CrossrefPubMedGoogle Scholar
  • 37 Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342 (8874): 759-766
    CrossrefPubMedGoogle Scholar
  • 38 Schömig A, Ndrepepa G, Kastrati A. Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. Eur Heart J 2006; 27 (16) 1900-1907
    CrossrefPubMedGoogle Scholar
  • 39 Rogers WJ, Canto JG, Lambrew CT. et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36 (07) 2056-2063
    CrossrefPubMedGoogle Scholar
  • 40 Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, López-Sendón J. GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359 (9304): 373-377
    CrossrefPubMedGoogle Scholar
  • 41 Nepper-Christensen L, Lønborg J, Høfsten DE. et al. Benefit from reperfusion with primary percutaneous coronary intervention beyond 12 hours of symptom duration in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2018; 11 (09) e006842
    CrossrefPubMedGoogle Scholar
  • 42 Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. Am Heart J 2007; 154 (06) 1065-1071
    CrossrefPubMedGoogle Scholar
  • 43 Hochman JS, Lamas GA, Buller CE. et al; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355 (23) 2395-2407
    CrossrefPubMedGoogle Scholar
  • 44 Menon V, Pearte CA, Buller CE. et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J 2009; 30 (02) 183-191
    CrossrefPubMedGoogle Scholar
  • 45 Mehta SR, Bassand JP, Chrolavicius S. et al; CURRENT-OASIS 7 Steering Committee. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008; 156 (06) 1080-1088.e1
    CrossrefPubMedGoogle Scholar
  • 46 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
    CrossrefPubMedGoogle Scholar
  • 47 Sabatine MS, Cannon CP, Gibson CM. et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352 (12) 1179-1189
    CrossrefPubMedGoogle Scholar
  • 48 Chen ZM, Pan HC, Chen YP. et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366 (9497): 1622-1632
    CrossrefPubMedGoogle Scholar
  • 49 Wiviott SD, Desai N, Murphy SA. et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011; 108 (07) 905-911
    CrossrefPubMedGoogle Scholar
  • 50 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedGoogle Scholar
  • 51 Schüpke S, Neumann FJ, Menichelli M. et al; ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019; 381 (16) 1524-1534
    CrossrefPubMedGoogle Scholar
  • 52 Park DW, Clare RM, Schulte PJ. et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA 2014; 312 (19) 2019-2027
    CrossrefPubMedGoogle Scholar
  • 53 Wald DS, Morris JK, Wald NJ. et al; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369 (12) 1115-1123
    CrossrefPubMedGoogle Scholar
  • 54 Gershlick AH, Khan JN, Kelly DJ. et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 2015; 65 (10) 963-972
    CrossrefPubMedGoogle Scholar
  • 55 Engstrøm T, Kelbæk H, Helqvist S. et al; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 386 (9994): 665-671
    CrossrefPubMedGoogle Scholar
  • 56 Smits PC, Abdel-Wahab M, Neumann FJ. et al; Compare-Acute Investigators. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017; 376 (13) 1234-1244
    CrossrefPubMedGoogle Scholar
  • 57 Elgendy IY, Mahmoud AN, Kumbhani DJ, Bhatt DL, Bavry AA. Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta-analysis of randomized trials. JACC Cardiovasc Interv 2017; 10 (04) 315-324
    CrossrefPubMedGoogle Scholar
  • 58 Mehta SR, Wood DA, Storey RF. et al; COMPLETE Trial Steering Committee and Investigators. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med 2019; 381 (15) 1411-1421
    CrossrefPubMedGoogle Scholar
  • 59 Levine GN, Bates ER, Blankenship JC. et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2016; 133 (11) 1135-1147
    CrossrefPubMedGoogle Scholar
  • 60 Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301 (02) 61-68
    CrossrefPubMedGoogle Scholar
  • 61 Grines CL, Browne KF, Marco J. et al; The Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328 (10) 673-679
    CrossrefPubMedGoogle Scholar
  • 62 Nunn CM, O'Neill WW, Rothbaum D. et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol 1999; 33 (03) 640-646
    CrossrefPubMedGoogle Scholar
  • 63 Meier B, King III SB, Gruentzig AR. et al. Repeat coronary angioplasty. J Am Coll Cardiol 1984; 4 (03) 463-466
    CrossrefPubMedGoogle Scholar
  • 64 Holmes Jr DR, Vlietstra RE, Smith HC. et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53 (12) 77C-81C
    CrossrefPubMedGoogle Scholar
  • 65 Schatz RA, Baim DS, Leon M. et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991; 83 (01) 148-161
    CrossrefPubMedGoogle Scholar
  • 66 Morice MC, Serruys PW, Sousa JE. et al; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346 (23) 1773-1780
    CrossrefPubMedGoogle Scholar
  • 67 Moses JW, Leon MB, Popma JJ. et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349 (14) 1315-1323
    CrossrefPubMedGoogle Scholar
  • 68 Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88 (03) 297-301
    CrossrefPubMedGoogle Scholar
  • 69 Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med 2004; 116 (04) 253-262
    CrossrefPubMedGoogle Scholar
  • 70 Sabaté M, Brugaletta S, Cequier A. et al. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. JACC Cardiovasc Interv 2014; 7 (01) 64-71
    CrossrefPubMedGoogle Scholar
  • 71 Räber L, Kelbæk H, Taniwaki M. et al; COMFORTABLE AMI Trial Investigators. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circ Cardiovasc Interv 2014; 7 (03) 355-364
    CrossrefPubMedGoogle Scholar
  • 72 Levine GN, Bates ER, Blankenship JC. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124 (23) e574-e651
    PubMedGoogle Scholar
  • 73 Bønaa KH, Mannsverk J, Wiseth R. et al; NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 2016; 375 (13) 1242-1252
    CrossrefPubMedGoogle Scholar
  • 74 Palmerini T, Benedetto U, Biondi-Zoccai G. et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2015; 65 (23) 2496-2507
    CrossrefPubMedGoogle Scholar
  • 75 Grines CL, Bonow RO, Casey Jr DE. et al; American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, American Dental Association, American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49 (06) 734-739
    CrossrefPubMedGoogle Scholar
  • 76 Spertus JA, Kettelkamp R, Vance C. et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113 (24) 2803-2809
    CrossrefPubMedGoogle Scholar
  • 77 Nasser M, Kapeliovich M, Markiewicz W. Late thrombosis of sirolimus-eluting stents following noncardiac surgery. Catheter Cardiovasc Interv 2005; 65 (04) 516-519
    CrossrefPubMedGoogle Scholar
  • 78 Garcia S, Stanberry L, Schmidt C. et al. Impact of COVID-19 pandemic on STEMI care: an expanded analysis from the United States. Catheter Cardiovasc Interv 2020
    Google Scholar
  • 79 De Luca G, Verdoia M, Cercek M. et al. Impact of COVID-19 pandemic on mechanical reperfusion for patients with STEMI. J Am Coll Cardiol 2020; 76 (20) 2321-2330
    CrossrefPubMedGoogle Scholar
  • 80 Xiang D, Xiang X, Zhang W. et al. Management and outcomes of patients with STEMI during the COVID-19 pandemic in China. J Am Coll Cardiol 2020; 76 (11) 1318-1324
    CrossrefPubMedGoogle Scholar
  • 81 Mahmud E, Dauerman HL, Welt FGP. et al. Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Catheter Cardiovasc Interv 2020; 96 (02) 336-345
    CrossrefPubMedGoogle Scholar
  • 82 Fulchand S. Covid-19 and cardiovascular disease. BMJ 2020; 369: m1997
    CrossrefPubMedGoogle Scholar
  • 83 Van De Werf F, Adgey J, Ardissino D. et al; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354 (9180): 716-722
    CrossrefPubMedGoogle Scholar
  • 84 Jolly SS, Yusuf S, Cairns J. et al; RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377 (9775): 1409-1420
    CrossrefPubMedGoogle Scholar
  • 85 Stone GW, Witzenbichler B, Guagliumi G. et al; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377 (9784): 2193-2204
    CrossrefPubMedGoogle Scholar
  • 86 Fahrni G, Wolfrum M, De Maria GL, Banning AP, Benedetto U, Kharbanda RK. Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: novel insights from an updated meta-analysis. J Am Heart Assoc 2016; 5 (07) e003515
    CrossrefPubMedGoogle Scholar
  • 87 Nichol G, Thomas E, Callaway CW. et al; Resuscitation Outcomes Consortium Investigators. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA 2008; 300 (12) 1423-1431
    CrossrefPubMedGoogle Scholar
  • 88 Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res 2015; 116 (12) 1887-1906
    CrossrefPubMedGoogle Scholar
  • 89 Garcia-Tejada J, Jurado-Román A, Rodríguez J. et al. Post-resuscitation electrocardiograms, acute coronary findings and in-hospital prognosis of survivors of out-of-hospital cardiac arrest. Resuscitation 2014; 85 (09) 1245-1250
    CrossrefPubMedGoogle Scholar